Terumo To Expand Cerebral Aneurysm Device Sales In The U.S., Other Markets
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Terumo plans to expand its product line of cerebral aneurysm and other brain treatment devices in the U.S. and overseas markets with hopes of reaching ¥10 billion ($992 million) in cerebral aneurism device sales by March 2011, Terumo said Sept. 3
You may also be interested in...
Terumo Acquires 5% Of Fuji Pharma To Grow Drug/Device Combo Product Business
Partners hope to capitalize on reform that narrows approval of pre-filled syringes to a single agency.
Terumo Acquires 5% Of Fuji Pharma To Grow Drug/Device Combo Product Business
Partners hope to capitalize on reform that narrows approval of pre-filled syringes to a single agency.
Terumo Acquires 5% of Fuji Pharma To Grow Drug/Device Combo Product Business
TOKYO - Japanese device maker Terumo Corp. reached an agreement to purchase 5 percent of Fuji Pharma common shares for jointly developing a drug and device combination product business in Japan - the first such convergence undertaking in a country where the government in the past administered the pharmaceutical and medical device markets almost separately